25 reports

  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
  • Chemokine
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • DEC 16, 2009: CHEMOCENTRYX INITIATES PHASE 2 CLINICAL TRIAL OF CCX354 FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

It targets chemokine (C-C Motif) receptor ## (CCR##).

  • Chemokine
  • Therapy
  • United States
  • World
  • ChemoCentryx, Inc.
  • DF-2755A - DRUG PROFILE
  • NUMBER OF PRODUCTS BY STAGE AND MECHANISM OF ACTIONS, H2 2017
  • Chemokine
  • Cytokine
  • United States
  • Product Initiative
  • Dompe Farmaceutici S.p.A.
  • R&D Progress Research and Development Brief
  • DISCONTINUED PRODUCTS, H2 2017
  • Chemokine
  • Therapy
  • United States
  • World
  • Product Initiative
  • C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Therapy Area
  • C-C Chemokine Receptor Type 3 (Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Products Glance
  • Chemokine
  • Therapy
  • World
  • Product Initiative
  • Pharmaxis Ltd
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance
  • Chemokine
  • United States
  • World
  • Product Initiative
  • Tobira Therapeutics, Inc.
  • CCX-650 - DRUG PROFILE
  • CHEMOCENTRYX INC
  • Chemokine
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
  • C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
  • Chemokine
  • HIV AIDS
  • Therapy
  • United States
  • Product Initiative
  • C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Drug Profiles
  • C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Dormant Projects
  • Chemokine
  • Therapy
  • Japan
  • Product Initiative
  • Kyowa Hakko Kirin Co., Ltd.
  • C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) Overview
  • C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Dormant Projects
  • Chemokine
  • Chronic Disease
  • World
  • Product Initiative
  • Pharmaxis Ltd
  • DF-2755A - Drug Profile
  • Number of Products under Development by Indication, H1 2016
  • Chemokine
  • United States
  • World
  • Product Initiative
  • Dompe Farmaceutici S.p.A.
  • BMS-457 - DRUG PROFILE
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2016
  • Chemokine
  • United States
  • World
  • Product Initiative
  • ChemoCentryx, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016
  • DISCONTINUED PRODUCTS, H2 2016
  • Chemokine
  • Cytokine
  • United States
  • Product Initiative
  • Dompe Farmaceutici S.p.A.
  • GENISTEIN - DRUG PROFILE
  • DORMANT PROJECTS, H1 2016
  • Chemokine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Juventas Therapeutics, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016
  • NUMBER OF PRODUCTS BY STAGE AND MECHANISM OF ACTION, H1 2016
  • Chemokine
  • HIV AIDS
  • Therapy
  • United States
  • Product Initiative
  • DISCONTINUED PRODUCTS, H1 2016
  • NUMBER OF PRODUCTS BY STAGE AND MECHANISM OF ACTION, H1 2016
  • Chemokine
  • Therapy
  • United States
  • Product Initiative
  • Dompe Farmaceutici S.p.A.
  • DISCONTINUED PRODUCTS, H2 2017
  • DORMANT PRODUCTS, H2 2017
  • Chemokine
  • Hospital
  • Targeted Therapy
  • Therapy
  • Juventas Therapeutics, Inc.
  • CCX-650 - DRUG PROFILE
  • DORMANT PROJECTS, H1 2016
  • Chemokine
  • United States
  • World
  • Product Initiative
  • ChemoCentryx, Inc.
  • The BL-8040 oncology platform is a short cyclic peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival.
  • DORMANT PROJECTS, H2 2016
  • Cancer
  • Chemokine
  • Research And Development
  • Therapy
  • BioLineRx Ltd.
  • Mechanism Of Action
  • (FILGRASTIM + PLERIXAFOR) - DRUG PROFILE
  • Cancer
  • Chemokine
  • R&D
  • Research And Development
  • BioLineRx Ltd.

Cytokine & Chemokine Testing Chemokines Cytokines Enzyme-Linked Immunosorbent Assay (ELlSA) D.

  • Chemokine
  • Europe
  • Japan
  • United States
  • World
  • 7.7 PIPELINE PROGRAMS TARGETING C-C MOTIF CHEMOKINE 4 (CCL4) AND C-C MOTIF CHEMOKINE 5 (CCL5)
  • Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of C-X-C Motif Chemokine 13, 2016
  • Arthritis
  • Chemokine
  • Pathology
  • World
  • Deals & Alliance
  • List of Tables
  • Jyant Technologies, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Chemokine
  • World
  • Litigation And Patent
  • Product Initiative
  • Jyant Technologies Inc
  • CHEMOCENTRYX, INC. - PRECLINICAL, 2016
  • CHEMOCENTRYX, INC. - PIPELINE BY TARGET, 2016
  • Chemokine
  • Therapy
  • World
  • Product Initiative
  • ChemoCentryx, Inc.
  • Target

Chemokine ## or Emoctakin or Granulocyte Chemotactic Protein ## or GCP## or Monocyte Derived Neutrophil Chemotactic Factor or MDNCF or Monocyte Derived Neutrophil Activating Peptide or MONAP or Neutrophil Activating Protein ## or NAP## or T Cell Chemotactic Factor or CXCL##), Leukotriene B## (LTB##

  • Chemokine
  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • Aradigm Corporation